The radiation dosimetry of In-111 pentetreotide
- Oak Ridge Inst. for Science and Education, TN (United States)
- Univ. Hospital Dijkzigt, Rotterdam (Netherlands); and others
In-111 Pentetreotide is a somatostatin receptor imaging agent for use in the scintigraphic localization of neuroendocrine tumors. Biokinetic data were gathered in two centers for determining the radiation dosimetry of this agent. In total, 10 patients were studied; their data were pooled to provide a single set of dose estimates. Scintigraphic data were used to quantify the activity in kidneys, liver, and spleen. Activity excreted in urine was also measured up to 48 hours post injection. These data were fit to a multicompartmental model using the Simulation Analysis And Modeling (SAAM) software. Excretion through the gastrointestinal (GI) tract was treated using the standard kinetic model of ICRP Publication 30, with input from the liver as determined by conservation of activity in the remainder of the model (no enterohepatic recycling was assumed). Residence times for the major organs (including GI organs) were averaged. Radiation dose estimates for all organs of the body, and the effective dose equivalent (EDE), were estimated using the MIRDOSE 3 software. Kidneys, spleen, and urinary bladder are all estimated to receive between 0.3 and 0.5 mGy/MBq. The lower large intestine wall receives approximately 0.08 mGy/MBq; all is approximately 0.1 mSv/MBq. These data should be used as the basis for the dosimetry of this agent.
- DOE Contract Number:
- AC05-76OR00033
- OSTI ID:
- 441635
- Report Number(s):
- CONF-950603--
- Journal Information:
- Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: Suppl.5 Vol. 36; ISSN 0161-5505; ISSN JNMEAQ
- Country of Publication:
- United States
- Language:
- English
Similar Records
Compartmental modeling of and radiation dose estimates for {sup 186}Re NR-LU-10 monoclonal antibody
Primary lung cancer: Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies